Skip to Content
Stock Analyst Update

Bayer’s Announced Acquisition Adds Needed Boost

The wide-moat drug manufacture plans to acquire Asklepios BioPharmaceuticals.

Mentioned:

Bayer’s (BAYRY) announced acquisition of Asklepios BioPharmaceuticals provides a needed boost to the firm’s drug pipeline in areas of unmet medical need. With the patent loss approaching for cardiovascular Xarelto as early as 2024 in some geographies, the acquisition helps to address the needed pipeline expansion. The acquisition also shows an increase in risk tolerance that Bayer needs in drug development, where conservative strategies don’t work well as payers tend to focus rewards on significant advancements in therapies. While the acquisition looks solid from a strategic perspective, we don’t expect any major changes to our fair value estimate, with the upfront $2 billion payment (followed by $2 billion potentially in milestone payments) largely offset by future potential new drug sales. Also, the increased focus on true innovation in the pipeline helps to reinforce our wide moat rating for the company.

The Asklepios acquisition should provide Bayer with a stronger entrenchment in cell and gene therapy with a focus on several rare diseases. Pipeline therapies targeting neuromuscular Pompe disease, neurological Parkinson’s disease, and congestive heart failure look the most advanced, with multiple mid-stage studies expected to read out over the next two years. The timing of these studies is important to set up Bayer with the needed next generation of drugs to address the patent expirations for Xarelto and the increasing competition on ophthalmology drug Eylea. Additionally, while the data is limited for several of Asklepios’ pipeline drugs, the firm’s drug development success has already been shown with out-licensed technology, including a license for the use of self-complementary DNA technology (scAAV) for the treatment of spinal muscular atrophy (SMA) to AveXis/Novartis.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Damien Conover does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.